Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:approves |
gptkb:1992
gptkb:FDA |
| gptkbp:brand |
gptkb:Pexeva
Paxil CR |
| gptkbp:clinical_trial |
for anxiety
for OCD for PTSD for depression for panic disorder |
| gptkbp:contraindication |
pregnancy
breastfeeding severe liver disease allergy to paroxetine |
| gptkbp:discontinued |
in some countries
|
| gptkbp:dosage_form |
20 mg to 50 mg daily
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Paxil
|
| gptkbp:ingredients |
C19 H20 FN O3 S
|
| gptkbp:interacts_with |
gptkb:beer
MAO inhibitors blood thinners NSAI Ds other SSR Is |
| gptkbp:is_atype_of |
N06 A B05
|
| gptkbp:is_available_on |
gptkb:tablet
suspension extended-release tablet |
| gptkbp:is_used_for |
gptkb:post-traumatic_stress_disorder
anxiety disorders obsessive-compulsive disorder major depressive disorder panic disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
21 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
gptkb:paroxetine
|
| gptkbp:side_effect |
nausea
drowsiness insomnia dry mouth weight gain sexual dysfunction |
| gptkbp:symptoms |
dizziness
nausea sleep disturbances irritability sensory disturbances |
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
3
|